ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $363.01B | 15.35% |
2TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $259.15B | 10.96% |
3ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 6.45% |
4MCK | MCKESSON CORP | Healthcare | $124.35B | 5.26% |
5HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 4.42% |
6REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 4.16% |
7ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 3.93% |
8CI | CIGNA GROUP | Healthcare | $78.07B | 3.30% |
9COR | CENCORA INC | Healthcare | $66.67B | 2.82% |
10CAH | CARDINAL HEALTH INC | Healthcare | $64.29B | 2.72% |
11BSX | BOSTON SCIENTIFIC CORP | Healthcare | $64.07B | 2.71% |
12EW | EDWARDS LIFESCIENCES CORP | Healthcare | $60.84B | 2.57% |
13BDX | BECTON DICKINSON & CO | Healthcare | $58.76B | 2.48% |
14IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 2.33% |
15VEEV | VEEVA SYSTEMS INC | Healthcare | $48.96B | 2.07% |
16IQV | IQVIA HOLDINGS INC | Healthcare | $44.68B | 1.89% |
17MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 1.46% |
18ZTS | ZOETIS INC | Healthcare | $33.71B | 1.43% |
19RMD | RESMED INC | Healthcare | $33.60B | 1.42% |
20ILMN | ILLUMINA INC | Healthcare | $31.68B | 1.34% |
21DXCM | DEXCOM INC | Healthcare | $30.35B | 1.28% |
22LH | LABCORP HOLDINGS INC | Healthcare | $30.23B | 1.28% |
23WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $28.65B | 1.21% |
24DGX | QUEST DIAGNOSTICS INC | Healthcare | $28.57B | 1.21% |
25UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 1.07% |
26STE | STERIS PLC | Healthcare | $24.61B | 1.04% |
27THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 0.97% |
28ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 0.84% |
29RVTY | REVVITY INC | Healthcare | $17.53B | 0.74% |
30EXEL | EXELIXIS INC | Healthcare | $17.04B | 0.72% |
31CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $16.33B | 0.69% |
32SOLV | SOLVENTUM CORP | Healthcare | $15.07B | 0.64% |
33EHC | ENCOMPASS HEALTH CORP | Healthcare | $13.82B | 0.58% |
34COO | COOPER COMPANIES INC | Healthcare | $11.83B | 0.50% |
35ALGN | ALIGN TECHNOLOGY INC | Healthcare | $11.77B | 0.50% |
36HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.49% |
37UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 0.47% |
38DVA | DAVITA INC | Healthcare | $10.95B | 0.46% |
39PODD | INSULET CORP | Healthcare | $10.36B | 0.44% |
40TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.41% |
41GMED | GLOBUS MEDICAL INC | Healthcare | $9.58B | 0.40% |
42HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 0.40% |
43ATR | APTARGROUP INC | Healthcare | $8.98B | 0.38% |
44HQY | HEALTHEQUITY INC | Healthcare | $8.52B | 0.36% |
45CHE | CHEMED CORP | Healthcare | $7.16B | 0.30% |
46LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 0.28% |
47TFX | TELEFLEX INC | Healthcare | $6.07B | 0.26% |
48DOCS | DOXIMITY INC | Healthcare | $5.92B | 0.25% |
49HAE | HAEMONETICS CORP | Healthcare | $5.59B | 0.24% |
50CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $5.44B | 0.23% |
51LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $5.38B | 0.23% |
52OPCH | OPTION CARE HEALTH INC | Healthcare | $4.75B | 0.20% |
53ITGR | INTEGER HOLDINGS CORP | Healthcare | $4.30B | 0.18% |
54NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.17% |
55ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.12% |
56PGNY | PROGYNY INC | Healthcare | $2.69B | 0.11% |
57ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.11% |
58MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.10% |
59PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.09% |
60AZTA | AZENTA INC | Healthcare | $1.92B | 0.08% |
61ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.08% |
62CERT | CERTARA INC | Healthcare | $1.82B | 0.08% |
63ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.07% |
64HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.07% |
65CNMD | CONMED CORP | Healthcare | $1.50B | 0.06% |
66USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.47B | 0.06% |
67PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.06% |
68INVA | INNOVIVA INC | Healthcare | $1.35B | 0.06% |
69AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.05% |
70NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.05% |
71COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.03% |
72DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.03% |
73FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.03% |
74FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.03% |
75CLYM | CLIMB BIO INC | Healthcare | $639M | 0.03% |
76NRC | NRC HEALTH | Healthcare | $565M | 0.02% |
77PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.02% |
78EMBC | EMBECTA CORP | Healthcare | $364M | 0.02% |
79EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.01% |
80INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.01% |
81PDEX | PRO DEX INC | Healthcare | $216M | 0.01% |
82ELMD | ELECTROMED INC | Healthcare | $204M | 0.01% |
83KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.01% |
84ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.01% |
85INGN | INOGEN INC | Healthcare | $146M | 0.01% |
86JYNT | JOINT CORP | Healthcare | $92M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $2.37T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 53% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 22%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 21.0% | 4.3% |
| 3 yearsp.a. | 12.8% | -16.7% |
| 5 yearsp.a. | 8.5% | 2.3% |
| 10 yearsp.a. | 11.6% | 5.9% |
| Since inceptionp.a. | 8.3% | -0.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 22.5% | 3.9% |
| 2025 | 12.1% | -31.4% |
| 2024 | 0.6% | -6.9% |
| 2023 | -1.7% | -13.9% |
| 2022 | 0.8% | 75.6% |
| 2021 | 25.4% | 82.8% |
| 2020 | 15.2% | 5.8% |
| 2019 | 19.4% | -16.1% |
| 2018 | 4.9% | 14.2% |
| 2017 | 19.9% | -8.8% |
| 2016 | -1.2% | 24.6% |
| 2015 | 7.1% | -2.3% |
| 2014 | 20.7% | -11.8% |
| 2013 | 42.0% | -4.5% |
| 2012 | 21.8% | -5.1% |
| 2011 | 11.1% | 8.2% |
| 2010 | 8.3% | 5.0% |
| 2009 | 22.5% | 5.0% |
| 2008 | -21.2% | 2.9% |
| 2007 | 5.1% | -3.8% |
| 2006 | 7.2% | 15.6% |
| 2005 | 10.5% | 18.4% |
| 2004 | 4.7% | -5.2% |
| 2003 | 12.1% | -27.1% |
| 2002 | -21.2% | 18.5% |
| 2001 | -16.0% | -4.4% |
| 2000 | 48.2% | -55.1% |
| 1999 | -14.4% | -0.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare ShareIss1Y Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ShareIss1Y signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.